---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-073391"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:36:52.193563+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Viridian reports 2025 net loss of $342.6M; veligrotug PDUFA date June 30, 2026

## Summary
- Cash, cash equivalents and marketable securities were $874.7M as of Dec 31, 2025, up from $717.6M.
- Net loss for 2025 was $342.6M ($269.9M in 2024); R&D spend rose to $338.9M.
- PDUFA target action date for veligrotug BLA is June 30, 2026; Priority Review ongoing.
- MAA for veligrotug submitted to EMA in January 2026 for European approval.
- Phase 3 REVEAL-1 topline data for elegrobart on track for Q1 2026; REVEAL-2 for Q2 2026.

## SEC filing metadata
- accession: 0001193125-26-073391
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312526073391/0001193125-26-073391-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312526073391/d105707d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-073391
- JSON: https://secwatch.observer/filing/0001193125-26-073391.json
- Plain text: https://secwatch.observer/filing/0001193125-26-073391.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.